<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>6132917</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">30132078</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">6132917</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="publisher-id">1916</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.1007/s00702-018-1916-y</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Subject characteristics</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table 1</label><caption><p>Subject characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Controls (<italic>n</italic> = 27)</th><th align="left">Patients (<italic>n</italic> = 24)</th><th align="left">Difference</th></tr></thead><tbody><tr><td align="left">Age in years (<italic>M</italic>, SD)</td><td align="left">59.37 (8.54)</td><td align="left">63.42 (7.93)</td><td align="left">ns</td></tr><tr><td align="left">Education level (<italic>M</italic>, SD)</td><td align="left">6.15 (0.86)</td><td align="left">5.25 (1.11)</td><td align="left"><italic>U</italic> = 174.5, <italic>p</italic> = 0.003</td></tr><tr><td align="left">Gender</td><td align="left">11 females</td><td align="left">7 females</td><td align="left">ns</td></tr><tr><td align="left">Disease duration in years (<italic>M</italic>, SD)</td><td align="left">–</td><td align="left">4.08 (3.13)</td><td align="left">–</td></tr><tr><td align="left">LEDD in mg (<italic>M</italic>, SD)</td><td align="left">–</td><td align="left">796.29 (616.44)</td><td align="left">–</td></tr><tr><td align="left">UPDRS during ON phase (<italic>M</italic>, SD)</td><td align="left">–</td><td align="left">17.67 (7.66)</td><td align="left">–</td></tr><tr><td align="left">MoCA (<italic>M</italic>, SD)</td><td align="left">27.89 (1.89)</td><td align="left">26.88 (1.92)</td><td align="left">ns</td></tr><tr><td align="left">BDI</td><td align="left">22.96 (2.24)</td><td align="left">30.46 (7.12)</td><td align="left"><italic>U</italic> = 82.5, <italic>p</italic> &lt; 0.001</td></tr></tbody></table><table-wrap-foot><p><italic>LEDD</italic> Levodopa equivalent daily dose, <italic>UPDRS</italic> United Parkinson’s disease rating scale, <italic>MoCA</italic> montreal cognitive assessment, <italic>BDI</italic> Beck’s depression inventory</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Subject characteristics</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Controls (n = 27)</th><th align="left">Patients (n = 24)</th><th align="left">Difference</th></tr></thead><tbody><tr><td align="left">Age in years (M, SD)</td><td align="left">59.37 (8.54)</td><td align="left">63.42 (7.93)</td><td align="left">ns</td></tr><tr><td align="left">Education level (M, SD)</td><td align="left">6.15 (0.86)</td><td align="left">5.25 (1.11)</td><td align="left">U = 174.5, p = 0.003</td></tr><tr><td align="left">Gender</td><td align="left">11 females</td><td align="left">7 females</td><td align="left">ns</td></tr><tr><td align="left">Disease duration in years (M, SD)</td><td align="left">–</td><td align="left">4.08 (3.13)</td><td align="left">–</td></tr><tr><td align="left">LEDD in mg (M, SD)</td><td align="left">–</td><td align="left">796.29 (616.44)</td><td align="left">–</td></tr><tr><td align="left">UPDRS during ON phase (M, SD)</td><td align="left">–</td><td align="left">17.67 (7.66)</td><td align="left">–</td></tr><tr><td align="left">MoCA (M, SD)</td><td align="left">27.89 (1.89)</td><td align="left">26.88 (1.92)</td><td align="left">ns</td></tr><tr><td align="left">BDI</td><td align="left">22.96 (2.24)</td><td align="left">30.46 (7.12)</td><td align="left">U = 82.5, p &lt; 0.001</td></tr></tbody></table></div>LEDD Levodopa equivalent daily dose, UPDRS United Parkinson’s disease rating scale, MoCA montreal cognitive assessment, BDI Beck’s depression inventory</transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>Overview of clinical characteristics per patient</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table 2</label><caption><p>Overview of clinical characteristics per patient</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Patient</th><th align="left" rowspan="2">Age</th><th align="left" rowspan="2">Disease duration (years)</th><th align="left" rowspan="2">LEDD (mg)</th><th align="left" colspan="3">Parkinson-medication</th><th align="left" colspan="2">Time to scan since medication (h)</th><th align="left" colspan="2">UPDRS III (before scan)</th><th align="left" rowspan="2">Duration of pain (years)</th><th align="left" rowspan="2">Wearing-off<sup>a</sup></th></tr><tr><th align="left">Levodopa</th><th align="left">DA-agonist</th><th align="left">Other</th><th align="left">OFF</th><th align="left">ON</th><th align="left">OFF</th><th align="left">ON</th></tr></thead><tbody><tr><td align="left">#1</td><td char="." align="char">55</td><td char="." align="char">3.5</td><td char="." align="char">564</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">15.0</td><td align="left">1.0</td><td align="left">24</td><td align="left">18.5</td><td char="." align="char">3.00</td><td align="left">Yes</td></tr><tr><td align="left">#2</td><td char="." align="char">73</td><td char="." align="char">2.0</td><td char="." align="char">752</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">17.0</td><td align="left">1.0</td><td align="left">28</td><td align="left">20</td><td char="." align="char">8.00</td><td align="left">Yes</td></tr><tr><td align="left">#3</td><td char="." align="char">67</td><td char="." align="char">10.0</td><td char="." align="char">564</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">20.5</td><td align="left">1.0</td><td align="left">20</td><td align="left">17</td><td char="." align="char">30.00</td><td align="left">Yes</td></tr><tr><td align="left">#4</td><td char="." align="char">72</td><td char="." align="char">3.0</td><td char="." align="char">375</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">16.5</td><td align="left">1.5</td><td align="left">14</td><td align="left">17</td><td char="." align="char">3.00</td><td align="left">Yes</td></tr><tr><td align="left">#5</td><td char="." align="char">68</td><td char="." align="char">1.0</td><td char="." align="char">828</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">16.0</td><td align="left">2.5</td><td align="left">16</td><td align="left">11</td><td char="." align="char">0.00</td><td align="left">No</td></tr><tr><td align="left">#6</td><td char="." align="char">56</td><td char="." align="char">2.0</td><td char="." align="char">375</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">26.5</td><td align="left">2.0</td><td align="left">11</td><td align="left">7</td><td char="." align="char">1.00</td><td align="left">No</td></tr><tr><td align="left">#7</td><td char="." align="char">68</td><td char="." align="char">2.0</td><td char="." align="char">378</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">19.5</td><td align="left">5.5</td><td align="left">13</td><td align="left">13</td><td char="." align="char">0.00</td><td align="left">Yes</td></tr><tr><td align="left">#8</td><td char="." align="char">65</td><td char="." align="char">8.0</td><td char="." align="char">850</td><td align="left">Yes</td><td align="left"/><td align="left">MAO-B inhibitor (rasagiline), COMT inhibitor (entacapone)</td><td align="left">12.5</td><td align="left">1.5</td><td align="left">18</td><td align="left">Missing</td><td char="." align="char">1.00</td><td align="left">Yes</td></tr><tr><td align="left">#9</td><td char="." align="char">62</td><td char="." align="char">4.0</td><td char="." align="char">2780</td><td align="left">Yes</td><td align="left"/><td align="left">COMT inhibitor (entacapone)</td><td align="left">14.5</td><td align="left">3.0</td><td align="left">33</td><td align="left">18</td><td char="." align="char">3.00</td><td align="left">No</td></tr><tr><td align="left">#10</td><td char="." align="char">64</td><td char="." align="char">5.5</td><td char="." align="char">982</td><td align="left">Yes</td><td align="left">DA-agonist (pramipexol)</td><td align="left"/><td align="left">14.5</td><td align="left">2.0</td><td align="left">25</td><td align="left">30</td><td char="." align="char">0.25</td><td align="left">No</td></tr><tr><td align="left">#11</td><td char="." align="char">68</td><td char="." align="char">2.0</td><td char="." align="char">125</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">15.5</td><td align="left">2.5</td><td align="left">6</td><td align="left">7</td><td char="." align="char">3.00</td><td align="left">No</td></tr><tr><td align="left">#12</td><td char="." align="char">69</td><td char="." align="char">1.0</td><td char="." align="char">500</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">15.0</td><td align="left">8.0</td><td align="left">19</td><td align="left">19</td><td char="." align="char">0.00</td><td align="left">No</td></tr><tr><td align="left">#13</td><td char="." align="char">73</td><td char="." align="char">5.0</td><td char="." align="char">375</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">13.5</td><td align="left">3.5</td><td align="left">37</td><td align="left">32</td><td char="." align="char">5.00</td><td align="left">Yes</td></tr><tr><td align="left">#14</td><td char="." align="char">70</td><td char="." align="char">3.0</td><td char="." align="char">1548</td><td align="left">Yes</td><td align="left"/><td align="left">COMT inhibitor (entacapone)</td><td align="left">15.5</td><td align="left">1.5</td><td align="left">17</td><td align="left">19</td><td char="." align="char">5.00</td><td align="left">Yes</td></tr><tr><td align="left">#15</td><td char="." align="char">71</td><td char="." align="char">6.0</td><td char="." align="char">1038</td><td align="left">Yes</td><td align="left">DA-agonist (pramipexol)</td><td align="left"/><td align="left">8.5</td><td align="left">5.5</td><td align="left">35</td><td align="left">31</td><td char="." align="char">7.00</td><td align="left">Yes</td></tr><tr><td align="left">#16</td><td char="." align="char">47</td><td char="." align="char">6.0</td><td char="." align="char">1428</td><td align="left">Yes</td><td align="left">DA-agonist (ropinirol)</td><td align="left"/><td align="left">14.0</td><td align="left">1.0</td><td align="left">24</td><td align="left">9</td><td char="." align="char">0.00</td><td align="left">No</td></tr><tr><td align="left">#17</td><td char="." align="char">48</td><td char="." align="char">0.5</td><td char="." align="char">1000</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">15.0</td><td align="left">1.5</td><td align="left">6</td><td align="left">5</td><td char="." align="char">0.00</td><td align="left">Yes</td></tr><tr><td align="left">#18</td><td char="." align="char">56</td><td char="." align="char">6.0</td><td char="." align="char">935</td><td align="left">Yes</td><td align="left">DA-agonist (pramipexol)</td><td align="left">MAO-B inhibitor (rasagiline)</td><td align="left">13.0</td><td align="left">1.5</td><td align="left">31</td><td align="left">13</td><td char="." align="char">2.00</td><td align="left">Yes</td></tr><tr><td align="left">#19</td><td char="." align="char">66</td><td char="." align="char">1.0</td><td char="." align="char">90</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">16.5</td><td align="left">2.0</td><td align="left">26</td><td align="left">26</td><td char="." align="char">5.00</td><td align="left">No</td></tr><tr><td align="left">#20</td><td char="." align="char">53</td><td char="." align="char">5.0</td><td char="." align="char">615</td><td align="left">Yes</td><td align="left">DA-agonist (ropinirol)</td><td align="left"/><td align="left">19.5</td><td align="left">1.5</td><td align="left">22</td><td align="left">18</td><td char="." align="char">7.00</td><td align="left">Yes</td></tr><tr><td align="left">#21</td><td char="." align="char">72</td><td char="." align="char">13.0</td><td char="." align="char">1150</td><td align="left">Yes</td><td align="left">DA-agonist (pramipexol)</td><td align="left">MAO-B inhibitor (rasagiline)</td><td align="left">16.0</td><td align="left">2.0</td><td align="left">23</td><td align="left">26</td><td char="." align="char">0.00</td><td align="left">No</td></tr><tr><td align="left">#22</td><td char="." align="char">57</td><td char="." align="char">1.0</td><td char="." align="char">106</td><td align="left">No</td><td align="left">DA-agonist (pramipexol)</td><td align="left"/><td align="left">18.5</td><td align="left">4.5</td><td align="left">18</td><td align="left">12</td><td char="." align="char">2.00</td><td align="left">Yes</td></tr><tr><td align="left">#23</td><td char="." align="char">51</td><td char="." align="char">6.0</td><td char="." align="char">1645</td><td align="left">Yes</td><td align="left">DA-agonist (ropinirol)</td><td align="left">Amantadine</td><td align="left">14.0</td><td align="left">2.5</td><td align="left">25</td><td align="left">16</td><td char="." align="char">5.00</td><td align="left">No</td></tr><tr><td align="left">#24</td><td char="." align="char">61</td><td char="." align="char">1.5</td><td char="." align="char">108</td><td align="left">No</td><td align="left">DA-agonist (pramipexol)</td><td align="left"/><td align="left">27.0</td><td align="left">12.0</td><td align="left">15</td><td align="left">22</td><td char="." align="char">0.75</td><td align="left">Yes</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Wearing off was determined as having 2 or more symptoms that improved with medication-intake, based on (Martinez-Martin and Hernandez <xref ref-type="bibr" rid="CR25">2012</xref>). One patient took a combination of an NSAID (Ibuprofen) and acetaminophen on a daily basis, all other patients did not any have pharmacological intervention for their pain</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Overview of clinical characteristics per patient</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Patient</th><th align="left" rowspan="2">Age</th><th align="left" rowspan="2">Disease duration (years)</th><th align="left" rowspan="2">LEDD (mg)</th><th align="left" colspan="3">Parkinson-medication</th><th align="left" colspan="2">Time to scan since medication (h)</th><th align="left" colspan="2">UPDRS III (before scan)</th><th align="left" rowspan="2">Duration of pain (years)</th><th align="left" rowspan="2">Wearing-offa</th></tr><tr><th align="left">Levodopa</th><th align="left">DA-agonist</th><th align="left">Other</th><th align="left">OFF</th><th align="left">ON</th><th align="left">OFF</th><th align="left">ON</th></tr></thead><tbody><tr><td align="left">#1</td><td char="." align="char">55</td><td char="." align="char">3.5</td><td char="." align="char">564</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">15.0</td><td align="left">1.0</td><td align="left">24</td><td align="left">18.5</td><td char="." align="char">3.00</td><td align="left">Yes</td></tr><tr><td align="left">#2</td><td char="." align="char">73</td><td char="." align="char">2.0</td><td char="." align="char">752</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">17.0</td><td align="left">1.0</td><td align="left">28</td><td align="left">20</td><td char="." align="char">8.00</td><td align="left">Yes</td></tr><tr><td align="left">#3</td><td char="." align="char">67</td><td char="." align="char">10.0</td><td char="." align="char">564</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">20.5</td><td align="left">1.0</td><td align="left">20</td><td align="left">17</td><td char="." align="char">30.00</td><td align="left">Yes</td></tr><tr><td align="left">#4</td><td char="." align="char">72</td><td char="." align="char">3.0</td><td char="." align="char">375</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">16.5</td><td align="left">1.5</td><td align="left">14</td><td align="left">17</td><td char="." align="char">3.00</td><td align="left">Yes</td></tr><tr><td align="left">#5</td><td char="." align="char">68</td><td char="." align="char">1.0</td><td char="." align="char">828</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">16.0</td><td align="left">2.5</td><td align="left">16</td><td align="left">11</td><td char="." align="char">0.00</td><td align="left">No</td></tr><tr><td align="left">#6</td><td char="." align="char">56</td><td char="." align="char">2.0</td><td char="." align="char">375</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">26.5</td><td align="left">2.0</td><td align="left">11</td><td align="left">7</td><td char="." align="char">1.00</td><td align="left">No</td></tr><tr><td align="left">#7</td><td char="." align="char">68</td><td char="." align="char">2.0</td><td char="." align="char">378</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">19.5</td><td align="left">5.5</td><td align="left">13</td><td align="left">13</td><td char="." align="char">0.00</td><td align="left">Yes</td></tr><tr><td align="left">#8</td><td char="." align="char">65</td><td char="." align="char">8.0</td><td char="." align="char">850</td><td align="left">Yes</td><td align="left"/><td align="left">MAO-B inhibitor (rasagiline), COMT inhibitor (entacapone)</td><td align="left">12.5</td><td align="left">1.5</td><td align="left">18</td><td align="left">Missing</td><td char="." align="char">1.00</td><td align="left">Yes</td></tr><tr><td align="left">#9</td><td char="." align="char">62</td><td char="." align="char">4.0</td><td char="." align="char">2780</td><td align="left">Yes</td><td align="left"/><td align="left">COMT inhibitor (entacapone)</td><td align="left">14.5</td><td align="left">3.0</td><td align="left">33</td><td align="left">18</td><td char="." align="char">3.00</td><td align="left">No</td></tr><tr><td align="left">#10</td><td char="." align="char">64</td><td char="." align="char">5.5</td><td char="." align="char">982</td><td align="left">Yes</td><td align="left">DA-agonist (pramipexol)</td><td align="left"/><td align="left">14.5</td><td align="left">2.0</td><td align="left">25</td><td align="left">30</td><td char="." align="char">0.25</td><td align="left">No</td></tr><tr><td align="left">#11</td><td char="." align="char">68</td><td char="." align="char">2.0</td><td char="." align="char">125</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">15.5</td><td align="left">2.5</td><td align="left">6</td><td align="left">7</td><td char="." align="char">3.00</td><td align="left">No</td></tr><tr><td align="left">#12</td><td char="." align="char">69</td><td char="." align="char">1.0</td><td char="." align="char">500</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">15.0</td><td align="left">8.0</td><td align="left">19</td><td align="left">19</td><td char="." align="char">0.00</td><td align="left">No</td></tr><tr><td align="left">#13</td><td char="." align="char">73</td><td char="." align="char">5.0</td><td char="." align="char">375</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">13.5</td><td align="left">3.5</td><td align="left">37</td><td align="left">32</td><td char="." align="char">5.00</td><td align="left">Yes</td></tr><tr><td align="left">#14</td><td char="." align="char">70</td><td char="." align="char">3.0</td><td char="." align="char">1548</td><td align="left">Yes</td><td align="left"/><td align="left">COMT inhibitor (entacapone)</td><td align="left">15.5</td><td align="left">1.5</td><td align="left">17</td><td align="left">19</td><td char="." align="char">5.00</td><td align="left">Yes</td></tr><tr><td align="left">#15</td><td char="." align="char">71</td><td char="." align="char">6.0</td><td char="." align="char">1038</td><td align="left">Yes</td><td align="left">DA-agonist (pramipexol)</td><td align="left"/><td align="left">8.5</td><td align="left">5.5</td><td align="left">35</td><td align="left">31</td><td char="." align="char">7.00</td><td align="left">Yes</td></tr><tr><td align="left">#16</td><td char="." align="char">47</td><td char="." align="char">6.0</td><td char="." align="char">1428</td><td align="left">Yes</td><td align="left">DA-agonist (ropinirol)</td><td align="left"/><td align="left">14.0</td><td align="left">1.0</td><td align="left">24</td><td align="left">9</td><td char="." align="char">0.00</td><td align="left">No</td></tr><tr><td align="left">#17</td><td char="." align="char">48</td><td char="." align="char">0.5</td><td char="." align="char">1000</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">15.0</td><td align="left">1.5</td><td align="left">6</td><td align="left">5</td><td char="." align="char">0.00</td><td align="left">Yes</td></tr><tr><td align="left">#18</td><td char="." align="char">56</td><td char="." align="char">6.0</td><td char="." align="char">935</td><td align="left">Yes</td><td align="left">DA-agonist (pramipexol)</td><td align="left">MAO-B inhibitor (rasagiline)</td><td align="left">13.0</td><td align="left">1.5</td><td align="left">31</td><td align="left">13</td><td char="." align="char">2.00</td><td align="left">Yes</td></tr><tr><td align="left">#19</td><td char="." align="char">66</td><td char="." align="char">1.0</td><td char="." align="char">90</td><td align="left">Yes</td><td align="left"/><td align="left"/><td align="left">16.5</td><td align="left">2.0</td><td align="left">26</td><td align="left">26</td><td char="." align="char">5.00</td><td align="left">No</td></tr><tr><td align="left">#20</td><td char="." align="char">53</td><td char="." align="char">5.0</td><td char="." align="char">615</td><td align="left">Yes</td><td align="left">DA-agonist (ropinirol)</td><td align="left"/><td align="left">19.5</td><td align="left">1.5</td><td align="left">22</td><td align="left">18</td><td char="." align="char">7.00</td><td align="left">Yes</td></tr><tr><td align="left">#21</td><td char="." align="char">72</td><td char="." align="char">13.0</td><td char="." align="char">1150</td><td align="left">Yes</td><td align="left">DA-agonist (pramipexol)</td><td align="left">MAO-B inhibitor (rasagiline)</td><td align="left">16.0</td><td align="left">2.0</td><td align="left">23</td><td align="left">26</td><td char="." align="char">0.00</td><td align="left">No</td></tr><tr><td align="left">#22</td><td char="." align="char">57</td><td char="." align="char">1.0</td><td char="." align="char">106</td><td align="left">No</td><td align="left">DA-agonist (pramipexol)</td><td align="left"/><td align="left">18.5</td><td align="left">4.5</td><td align="left">18</td><td align="left">12</td><td char="." align="char">2.00</td><td align="left">Yes</td></tr><tr><td align="left">#23</td><td char="." align="char">51</td><td char="." align="char">6.0</td><td char="." align="char">1645</td><td align="left">Yes</td><td align="left">DA-agonist (ropinirol)</td><td align="left">Amantadine</td><td align="left">14.0</td><td align="left">2.5</td><td align="left">25</td><td align="left">16</td><td char="." align="char">5.00</td><td align="left">No</td></tr><tr><td align="left">#24</td><td char="." align="char">61</td><td char="." align="char">1.5</td><td char="." align="char">108</td><td align="left">No</td><td align="left">DA-agonist (pramipexol)</td><td align="left"/><td align="left">27.0</td><td align="left">12.0</td><td align="left">15</td><td align="left">22</td><td char="." align="char">0.75</td><td align="left">Yes</td></tr></tbody></table></div>aWearing off was determined as having 2 or more symptoms that improved with medication-intake, based on (Martinez-Martin and Hernandez ???). One patient took a combination of an NSAID (Ibuprofen) and acetaminophen on a daily basis, all other patients did not any have pharmacological intervention for their pain</transformed-table></extracted-table><extracted-table><table-id>Tab3</table-id><table-label>Table 3</table-label><table-caption>Overview of types of pain according to the pain categories of Ford (2010), ‘Headache’ was added as a category</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table 3</label><caption><p>Overview of types of pain according to the pain categories of Ford (<xref ref-type="bibr" rid="CR17">2010</xref>), ‘Headache’ was added as a category</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Type of pain</th><th align="left">Patients (%)</th><th align="left">Controls (%)</th></tr></thead><tbody><tr><td align="left">Musculoskeletal</td><td align="left">16 (66.7%)</td><td align="left">9 (33.3%)</td></tr><tr><td align="left">Dystonic</td><td align="left">3 (12.5%)</td><td align="left">0</td></tr><tr><td align="left">Neuropathic/radicular</td><td align="left">5 (20.8%)</td><td align="left">0</td></tr><tr><td align="left">Central</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Akathisia</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Headache</td><td align="left">0</td><td align="left">2 (7.4%)</td></tr></tbody></table><table-wrap-foot><p>Multiple types of pain for a single subject were possible</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Overview of types of pain according to the pain categories of Ford (???), ‘Headache’ was added as a category</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left">Type of pain</th><th align="left">Patients (%)</th><th align="left">Controls (%)</th></tr></thead><tbody><tr><td align="left">Musculoskeletal</td><td align="left">16 (66.7%)</td><td align="left">9 (33.3%)</td></tr><tr><td align="left">Dystonic</td><td align="left">3 (12.5%)</td><td align="left">0</td></tr><tr><td align="left">Neuropathic/radicular</td><td align="left">5 (20.8%)</td><td align="left">0</td></tr><tr><td align="left">Central</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Akathisia</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Headache</td><td align="left">0</td><td align="left">2 (7.4%)</td></tr></tbody></table></div>Multiple types of pain for a single subject were possible</transformed-table></extracted-table><extracted-table><table-id>Tab4</table-id><table-label>Table 4</table-label><table-caption>Differences on pain scores between PD (ON and OFF phase) and healthy controls, tested with Mann–Whitney’s U test</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table 4</label><caption><p>Differences on pain scores between PD (ON and OFF phase) and healthy controls, tested with Mann–Whitney’s <italic>U</italic> test</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="3">HC versus PD OFF</th><th align="left" colspan="3">HC versus PD ON</th></tr><tr><th align="left"/><th align="left">HC (<italic>M</italic>, SD)</th><th align="left">PD OFF (<italic>M</italic>, SD)</th><th align="left">Difference</th><th align="left">Controls (<italic>M</italic>, SD)</th><th align="left">PD ON (<italic>M</italic>, SD)</th><th align="left">Difference</th></tr></thead><tbody><tr><td align="left">CAS intensity</td><td align="left">4.35 (9.38)</td><td align="left">15.87 (22.09)</td><td align="left">U = 413.00, <italic>p</italic> = 0.010</td><td align="left">4.35 (9.38)</td><td align="left">15.91 (18.77)</td><td align="left">U = 405.00, <italic>p</italic> = 0.037</td></tr><tr><td align="left">CAS affect</td><td align="left">2.81 (6.89)</td><td align="left">15.74 (22.49)</td><td align="left">U = 425.00, <italic>p</italic> = 0.004</td><td align="left">2.81 (6.89)</td><td align="left">16.78 (20.28)</td><td align="left">U = 416.00, <italic>p</italic> = 0.019</td></tr></tbody></table><table-wrap-foot><p><italic>PD</italic> Parkinson’s disease, <italic>HC</italic> Healthy controls, <italic>CAS</italic> colored analogue scale</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 4<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Differences on pain scores between PD (ON and OFF phase) and healthy controls, tested with Mann–Whitney’s U test</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="3">HC versus PD OFF</th><th align="left" colspan="3">HC versus PD ON</th></tr><tr><th align="left"/><th align="left">HC (M, SD)</th><th align="left">PD OFF (M, SD)</th><th align="left">Difference</th><th align="left">Controls (M, SD)</th><th align="left">PD ON (M, SD)</th><th align="left">Difference</th></tr></thead><tbody><tr><td align="left">CAS intensity</td><td align="left">4.35 (9.38)</td><td align="left">15.87 (22.09)</td><td align="left">U = 413.00, p = 0.010</td><td align="left">4.35 (9.38)</td><td align="left">15.91 (18.77)</td><td align="left">U = 405.00, p = 0.037</td></tr><tr><td align="left">CAS affect</td><td align="left">2.81 (6.89)</td><td align="left">15.74 (22.49)</td><td align="left">U = 425.00, p = 0.004</td><td align="left">2.81 (6.89)</td><td align="left">16.78 (20.28)</td><td align="left">U = 416.00, p = 0.019</td></tr></tbody></table></div>PD Parkinson’s disease, HC Healthy controls, CAS colored analogue scale</transformed-table></extracted-table><extracted-table><table-id>Tab5</table-id><table-label>Table 5</table-label><table-caption>Network measures for all groups and networks</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab5"><label>Table 5</label><caption><p>Network measures for all groups and networks</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Network</th><th align="left" colspan="3">HC versus PD OFF</th><th align="left" colspan="3">HC versus PD ON</th></tr><tr><th align="left">HC (<italic>M</italic>, SD)</th><th align="left">PD OFF (<italic>M</italic>, SD)</th><th align="left">Difference</th><th align="left">HC</th><th align="left">PD ON</th><th align="left">Difference</th></tr></thead><tbody><tr><td align="left">Whole brain</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="(" align="char"/><td align="left"/></tr><tr><td align="left"> GE</td><td char="." align="char">125.31 (60.26)</td><td char="." align="char">159.38 (44.05)</td><td align="left"><italic>F</italic>(1, 48) = 3.80; <italic>p</italic> = 0.057</td><td char="." align="char">125.31 (60.26)</td><td char="(" align="char">175.86 (72.24)</td><td align="left"><italic>F</italic>(1, 48) = 8.93; <italic>p</italic> = 0.004</td></tr><tr><td align="left">DMN</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> BC</td><td char="." align="char">0.02 (0.12)</td><td char="." align="char">− 0.01 (0.15)</td><td align="left">ns</td><td char="." align="char">0.02 (0.12)</td><td char="(" align="char">− 0.001 (0.13)</td><td align="left">ns</td></tr><tr><td align="left"> GE</td><td char="." align="char">0.30 (0.33)</td><td char="." align="char">0.37 (0.34)</td><td align="left">ns</td><td char="." align="char">0.30 (0.33)</td><td char="(" align="char">0.38 (0.25)</td><td align="left">ns</td></tr><tr><td align="left">Pain</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> BC</td><td char="." align="char">0.11 (0.23)</td><td char="." align="char">− 0.04 (0.26)</td><td align="left"><italic>F</italic>(1, 48) = 4.70; <italic>p</italic> = 0.035</td><td char="." align="char">0.11 (0.23)</td><td char="(" align="char">0.02 (0.30)</td><td align="left">ns</td></tr><tr><td align="left"> GE</td><td char="." align="char">11.40 (10.61)</td><td char="." align="char">23.74 (37.63)</td><td align="left">ns</td><td char="." align="char">11.40 (10.61)</td><td char="(" align="char">20.81 (21.30)</td><td align="left"><italic>F</italic>(1, 48) = 4.40; <italic>p</italic> = 0.041</td></tr></tbody></table><table-wrap-foot><p>MANCOVAs were performed, with average motion during the scan as a covariate</p><p><italic>BC</italic> betweenness centrality, <italic>GE</italic> global efficiency, <italic>DMN</italic> default mode network, <italic>PD</italic> Parkinson’s disease, <italic>HC</italic> healthy controls, <italic>ns</italic> not significant</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 5<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Network measures for all groups and networks</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Network</th><th align="left" colspan="3">HC versus PD OFF</th><th align="left" colspan="3">HC versus PD ON</th></tr><tr><th align="left">HC (M, SD)</th><th align="left">PD OFF (M, SD)</th><th align="left">Difference</th><th align="left">HC</th><th align="left">PD ON</th><th align="left">Difference</th></tr></thead><tbody><tr><td align="left">Whole brain</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="(" align="char"/><td align="left"/></tr><tr><td align="left"> GE</td><td char="." align="char">125.31 (60.26)</td><td char="." align="char">159.38 (44.05)</td><td align="left">F(1, 48) = 3.80; p = 0.057</td><td char="." align="char">125.31 (60.26)</td><td char="(" align="char">175.86 (72.24)</td><td align="left">F(1, 48) = 8.93; p = 0.004</td></tr><tr><td align="left">DMN</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> BC</td><td char="." align="char">0.02 (0.12)</td><td char="." align="char">− 0.01 (0.15)</td><td align="left">ns</td><td char="." align="char">0.02 (0.12)</td><td char="(" align="char">− 0.001 (0.13)</td><td align="left">ns</td></tr><tr><td align="left"> GE</td><td char="." align="char">0.30 (0.33)</td><td char="." align="char">0.37 (0.34)</td><td align="left">ns</td><td char="." align="char">0.30 (0.33)</td><td char="(" align="char">0.38 (0.25)</td><td align="left">ns</td></tr><tr><td align="left">Pain</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> BC</td><td char="." align="char">0.11 (0.23)</td><td char="." align="char">− 0.04 (0.26)</td><td align="left">F(1, 48) = 4.70; p = 0.035</td><td char="." align="char">0.11 (0.23)</td><td char="(" align="char">0.02 (0.30)</td><td align="left">ns</td></tr><tr><td align="left"> GE</td><td char="." align="char">11.40 (10.61)</td><td char="." align="char">23.74 (37.63)</td><td align="left">ns</td><td char="." align="char">11.40 (10.61)</td><td char="(" align="char">20.81 (21.30)</td><td align="left">F(1, 48) = 4.40; p = 0.041</td></tr></tbody></table></div>MANCOVAs were performed, with average motion during the scan as a covariateBC betweenness centrality, GE global efficiency, DMN default mode network, PD Parkinson’s disease, HC healthy controls, ns not significant</transformed-table></extracted-table><extracted-table><table-id>Tab6</table-id><table-label>Table 6</table-label><table-caption>One linear hierarchical regression was performed for each group (controls, PD ON and PD OFF medication)</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab6"><label>Table 6</label><caption><p>One linear hierarchical regression was performed for each group (controls, PD ON and PD OFF medication)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Group</th><th align="left">Step</th><th align="left">Independent variables</th><th align="left">Unstandardized B</th><th align="left">Std. error of B</th><th align="left">Standardized B</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">HC</td><td align="left">Step 1</td><td align="left">Average motion</td><td char="." align="char">− 0.055</td><td char="." align="char">18.62</td><td char="." align="char">− 0.001</td><td align="left">ns</td></tr><tr><td align="left"/><td align="left">Step 2</td><td align="left">Average motion</td><td char="." align="char">0.203</td><td char="." align="char">17.50</td><td char="." align="char">0.002</td><td align="left">ns</td></tr><tr><td align="left"/><td align="left"/><td align="left">BC of pain network</td><td char="." align="char">− 10.17</td><td char="." align="char">4.89</td><td char="." align="char">− 0.39</td><td align="left">0.049</td></tr><tr><td align="left"/><td align="left">Step 3</td><td align="left">Average motion</td><td char="." align="char">− 8.65</td><td char="." align="char">16.88</td><td char="." align="char">− 0.09</td><td align="left">ns</td></tr><tr><td align="left"/><td align="left"/><td align="left">BC of pain network</td><td char="." align="char">− 9.99</td><td char="." align="char">4.57</td><td char="." align="char">− 0.38</td><td align="left">0.039</td></tr><tr><td align="left"/><td align="left"/><td align="left">GE of pain network</td><td char="." align="char">− 0.218</td><td char="." align="char">0.10</td><td char="." align="char">− 0.38</td><td align="left">0.046</td></tr><tr><td align="left">PD OFF</td><td align="left">Step 1</td><td align="left">Average motion</td><td char="." align="char">− 5.43</td><td char="." align="char">65.11</td><td char="." align="char">− 0.02</td><td align="left">ns</td></tr><tr><td align="left"/><td align="left">Step 2</td><td align="left">Average motion</td><td char="." align="char">− 38.30</td><td char="." align="char">57.43</td><td char="." align="char">− 0.13</td><td align="left">ns</td></tr><tr><td align="left"/><td align="left"/><td align="left">GE of pain network</td><td char="." align="char">0.171</td><td char="." align="char">0.059</td><td char="." align="char">0.55</td><td align="left">0.009</td></tr><tr><td align="left">PD ON</td><td align="left">Step 1</td><td align="left">Average motion</td><td char="." align="char">27.32</td><td char="." align="char">36.34</td><td char="." align="char">0.158</td><td align="left">ns</td></tr></tbody></table><table-wrap-foot><p>To control for motion, average motion during scanning was entered at Step 1 as a covariate, after which a forward stepwise method was used to add significant independent variables to the model</p><p><italic>BC</italic> betweenness centrality, <italic>GE</italic> global efficiency, <italic>ns</italic> not significant</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 6<div xmlns="http://www.w3.org/1999/xhtml" class="caption">One linear hierarchical regression was performed for each group (controls, PD ON and PD OFF medication)</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left">Group</th><th align="left">Step</th><th align="left">Independent variables</th><th align="left">Unstandardized B</th><th align="left">Std. error of B</th><th align="left">Standardized B</th><th align="left">p value</th></tr></thead><tbody><tr><td align="left">HC</td><td align="left">Step 1</td><td align="left">Average motion</td><td char="." align="char">− 0.055</td><td char="." align="char">18.62</td><td char="." align="char">− 0.001</td><td align="left">ns</td></tr><tr><td align="left"/><td align="left">Step 2</td><td align="left">Average motion</td><td char="." align="char">0.203</td><td char="." align="char">17.50</td><td char="." align="char">0.002</td><td align="left">ns</td></tr><tr><td align="left"/><td align="left"/><td align="left">BC of pain network</td><td char="." align="char">− 10.17</td><td char="." align="char">4.89</td><td char="." align="char">− 0.39</td><td align="left">0.049</td></tr><tr><td align="left"/><td align="left">Step 3</td><td align="left">Average motion</td><td char="." align="char">− 8.65</td><td char="." align="char">16.88</td><td char="." align="char">− 0.09</td><td align="left">ns</td></tr><tr><td align="left"/><td align="left"/><td align="left">BC of pain network</td><td char="." align="char">− 9.99</td><td char="." align="char">4.57</td><td char="." align="char">− 0.38</td><td align="left">0.039</td></tr><tr><td align="left"/><td align="left"/><td align="left">GE of pain network</td><td char="." align="char">− 0.218</td><td char="." align="char">0.10</td><td char="." align="char">− 0.38</td><td align="left">0.046</td></tr><tr><td align="left">PD OFF</td><td align="left">Step 1</td><td align="left">Average motion</td><td char="." align="char">− 5.43</td><td char="." align="char">65.11</td><td char="." align="char">− 0.02</td><td align="left">ns</td></tr><tr><td align="left"/><td align="left">Step 2</td><td align="left">Average motion</td><td char="." align="char">− 38.30</td><td char="." align="char">57.43</td><td char="." align="char">− 0.13</td><td align="left">ns</td></tr><tr><td align="left"/><td align="left"/><td align="left">GE of pain network</td><td char="." align="char">0.171</td><td char="." align="char">0.059</td><td char="." align="char">0.55</td><td align="left">0.009</td></tr><tr><td align="left">PD ON</td><td align="left">Step 1</td><td align="left">Average motion</td><td char="." align="char">27.32</td><td char="." align="char">36.34</td><td char="." align="char">0.158</td><td align="left">ns</td></tr></tbody></table></div>To control for motion, average motion during scanning was entered at Step 1 as a covariate, after which a forward stepwise method was used to add significant independent variables to the modelBC betweenness centrality, GE global efficiency, ns not significant</transformed-table></extracted-table></extracted-tables-set>